Abstract: The present invention relates to the fields of medicine and molecular diagnostics. In particular, it relates to a novel method for the treatment, prevention and/or delay of cancer and to a diagnostic method involving detection of a novel auto-active and intracellular mutant of MET.

Abstract: The present disclosure concerns a method and system for imaging a molecular strand (MS). The method comprises providing a sample volume (SV) comprising the strand (MS); providing an excitation beam (EB) having an excitation focus (EF) in the sample volume (SV); scanning the excitation focus (EF) in the sample volume (SV) along a one dimensional scanning line (SL); trapping an end of the strand (MS) in the sample volume (SV) and extending the strand (MS) along a one-dimensional trapping line (LL) parallel to the scanning line (SL); aligning the trapping line (LL) to coincide with the scanning line (SL) to have the scanning excitation focus (EF) coincide with the strand (MS); and recording the fluorescence response (FR) as a function of a plurality of distinct scanning positions (X0) of the excitation focus (EF) along the scanning line (SL).

Abstract: The invention relates to the use of sphingosine based compounds, in particular phytosphingosine compounds, in the protection of hydroxyapatite containing materials such as teeth and bone. Such compounds are especially useful in the treatment and prevention of dental caries, dental erosion, dentine hypersensitivity and tartar (dental calculus) formation. Methods and devices are also provided for preventing biofilm formation using sphingosine based compounds. Compositions comprising sphingosine based compounds are also provided.

Abstract: The disclosure relates to the use of altered BRI2 levels as a biomarker for the risk of developing Alzheimer's disease. Novel treatments based on altered BRI2 levels and anti-BRI2 antibodies are also provided.

Abstract: The invention relates to methods for predicting a clinical response to B-lymphocyte inhibiting or depleting therapies (BCIDT) using expression levels of genes of the Type I INF pathway. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with B-lymphocyte inhibiting or depleting therapy.

Abstract: The present invention relates generally to the field of plant molecular biology and agents useful in the manipulation of plant physiological and biochemical properties. More particularly, the present invention provides genetic and proteinaceous agents capable of modulating or altering the level of acidity or alkalinity in a cell, group of cells, organelle, part or reproductive portion of a plant. Genetically altered plants, plant parts, progeny, subsequent generations and reproductive material including flowers or flowering parts having cells exhibiting an altered cellular including vacuolar pH compared to a non-genetically altered plant are also provided.